Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept vs Adalimumab in Early Seropositive Rheumatoid Arthritis
2023-506450-20-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 3, randomised, single-blind trial in rheumatoid arthritis (RA) comparing Abatacept + methotrexate with Adalimumab + methotrexate (2 arms). Primary endpoint: ACR50 response in shared epitope positive participants at Week 24. Planned start Jan 2024; status: authorised.
02
Drugs
abataceptadalimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2023-506450-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506450-20-00.